Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 8/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.38 |
| ▸ | CDC42BPB | Q9Y5S2 | 3/20 | 0.38 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | PRKX | P51817 | 1/20 | 0.37 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.37 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.37 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.37 |
| ▸ | IKBKB | O14920 | 1/20 | 0.36 |
| ▸ | CHUK | O15111 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2541858 | 0.82 | LOX (0.41) | — | |
| SCHEMBL19128754 | 0.81 | HRH1 (0.43) | CHRNB2CHRNA4ROCK1ROCK2HTR1A | |
| SCHEMBL8636961 | 0.81 | LOX (0.43) | — | |
| Magnesium Chloride Anhydrous SCHEMBL28457245 | 0.77 | LOX (0.34) | — | |
| SCHEMBL20898791 | 0.77 | CHRNB2 (0.46) | CHRNB2CHRNA4ROCK1ROCK2KCNH2 | |
| SCHEMBL3984986 | 0.76 | CHRNB2 (0.55) | CHRNB2CHRNA4ROCK1ROCK2KCNH2 | |
| Hydrochloric Acid SCHEMBL3296534 | 0.75 | CHRNB2 (0.54) | CHRNB2CHRNA4ROCK1ROCK2KCNH2 | |
| SCHEMBL26668368 | 0.75 | CHRNB2 (0.54) | CHRNB2CHRNA4ROCK1ROCK2KCNH2 | |
| SCHEMBL26665874 | 0.75 | CHRNB2 (0.54) | CHRNB2CHRNA4ROCK1ROCK2KCNH2 | |
| SCHEMBL22825608 | 0.73 | CHRNB2 (0.49) | CHRNB2CHRNA4ROCK1ROCK2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2573079-A2 | Benzimidazole quinolinones and uses thereof | Novartis Vaccines and Diagnostics, Inc. (US) | 2013-03-27 | — | — | EP | disclosed |
| US-7825132-B2 | Inhibition of FGFR3 and treatment of multiple myeloma | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20090281100-A1 | Benzimidazole quinolinones and uses thereof | BARSANTI PAUL A | 2009-11-12 | — | — | US | disclosed |
| EP-1539754-A4 | BENZIMIDAZOLE QUINOLINONES AND USES THEREOF | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2009-02-25 | — | — | EP | disclosed |
| US-7470709-B2 | Benzimidazole quinolinones and uses thereof | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| EP-1692085-A2 | INHIBITION OF FGFR3 AND TREATMENT OF MULTIPLE MYELOMA | Chiron Corporation (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20050261307-A1 | Inhibition of FGFR3 and treatment of multiple myeloma | CHIRON CORPORATION | 2005-11-24 | — | — | US | disclosed |
| US-20050256157-A1 | Combination therapy with CHK1 inhibitors | CHIRON CORPORATION | 2005-11-17 | — | — | US | disclosed |
| US-20050203101-A1 | Benzimidazole quinolinones and uses thereof | CHIRON CORPORATION | 2005-09-15 | — | — | US | disclosed |
| EP-1539754-A2 | BENZIMIDAZOLE QUINOLINONES AND USES THEREOF | Chiron Corporation (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2005047244-A2 | INHIBITION OF FGFR3 AND TREATMENT OF MULTIPLE MYELOMA | CHIRON CORPORATION (US) | 2005-05-26 | — | — | WO | disclosed |
| US-20040092535-A1 | Benzimidazole quinolinones and uses thereof | CHIRON CORPORATION | 2004-05-13 | — | — | US | disclosed |
| WO-2004018419-A2 | BENZIMIDAZOLE QUINOLINONES AND USES THEREOF | CHIRON CORPORATION (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256157-A1 | Combination therapy with CHK1 inhibitors | CHEK1, CHEK2, RAD1 | CHRNB2 3617/4885CHRNA4 4050/4885ROCK1 1086/4885 |
| US-20050261307-A1 | Inhibition of FGFR3 and treatment of multiple myeloma | FGFR3, FGFR1, FGFR2 | CHRNB2 4829/4885CHRNA4 4703/4885ROCK1 1687/4885 |
| US-20090281100-A1 | Benzimidazole quinolinones and uses thereof | GAA, ALPI, IL4I1 | CHRNB2 3928/4885CHRNA4 3761/4885ROCK1 3209/4885 |
| US-20050203101-A1 | Benzimidazole quinolinones and uses thereof | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TP53, PBRM1 | CHRNB2 3068/4885CHRNA4 2323/4885ROCK1 1109/4885 |
| US-20040092535-A1 | Benzimidazole quinolinones and uses thereof | GAA, ALPI, IL4I1 | CHRNB2 4021/4885CHRNA4 3868/4885ROCK1 2742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.